The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Novadaq Technologies

Monday Biotech Deal Review: March 29, 2011

Welcome to your Monday Biotech Deal Review for March 28, 2011.  There was a flurry of financing activity last week, with over $76M raised or announced in biotech funds (not including the $60M Genome Canada investment announced by the Government of Canada).  Double-digit million-dollar deals included MethylGene’s $34.5M private placement announcement, Medicago’s $17M private placement announcement, and the closing of Novadaq’s $15M private placement.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: March 21, 2011

Welcome to your Monday Biotech Deal Review for March 21, 2011.  There was some interesting investment and commercial transactions announced and closed last week, including the $15M private placement announced by Novadaq, the $4M bond financing closed by SemBioSys and Pacgen’s announcement of a corporate makeover to accommodate its recent investments in the products of General Biologicals Corporation.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: February 7, 2011

Welcome to your Monday Biotech Deal Review for February 7, 2011.  It was a fairly busy week for Canadian biotech – Angiotech has followed suit in the U.S. on the heels of last week’s CCAA filing, a number of acquisitions were announced, and there was some activity in biotech licensing.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: November 15, 2010

Welcome to the Monday Biotech Deal Review for November 15, 2010.  Read on to learn about IMRIS’ proposed U.S. IPO, a mysterious merger in the making, and heart lasers (and how much they go for), together with your usual assortment of private placements, announcements and other biotech news.  Read more of this post

Monday Biotech Deal Review: March 29, 2010

This week’s Canadian biotech deals include an acquisition by Biovail, Hæmacure’s BIA filing comes to a predictable end, MethylGene finds $8.9 million in its couch cushions from some Ontario numbered corps, Leap Medical leaps ahead with $1 million from MSBiV and other Quebec favourites, and BioSyntech borrows against its SR&EDs.  Those, plus more securities, debt and commercial deals after the jump…

Monday Biotech Deal Review: March 1, 2010

This week saw a lot of offerings move forward, in the shadow of Anthera’s shrunken and postponed IPO, but the news wasn’t all good in Canada either. ConjuChem filed for restructuring, and other companies are still holding on by their teeth. See who’s who after the jump

Monday Biotech Deal Review: February 22, 2010

There was a lot of follow-up among Canadian biotech deals this week: letters of intent turning into definitive agreements, merged companies turning to consolidation, bids launched on schedule and wrapped up; as well as an average crop of new M&Eh and securities.  Start things off with an interesting (cross-border!) twist to the SIFT/SR&ED deals we’ve seen after the jump…

Follow

Get every new post delivered to your Inbox.

Join 123 other followers